Literature DB >> 8978273

Telomerase activity in reactive and neoplastic lymphoid tissues: infrequent detection of activity in Hodgkin's disease.

P Brousset1, T al Saati, N Chaouche, R C Zenou, D Schlaifer, S Chittal, G Delsol.   

Abstract

We used the recently described sensitive and rapid detection assay called telomeric repeat amplification protocol (TRAP) to detect telomerase activity in lymphoblastoid (n = 5) and lymphoma cell lines (n = 7), hyperplastic lymph nodes (n = 6) and tonsils (n = 5), and tissues involved by non-Hodgkin's lymphoma (NHL) (n = 43) and Hodgkin's disease (HD) (n = 14). Clearly evident telomerase activity was found in all lymphoblastoid and lymphoma cell lines, and in 34 of 43 cases (80%) of NHL. These results were expected because of the proliferative and immortal nature of the cell lines and most malignant cells. However, positive results were obtained with the TRAP assay in all hyperplastic lymph nodes and tonsils, which raises the issue of derepression of telomerase activity during an immune response. Telomerase activity alone therefore does not distinguish malignant lymphoid proliferations from reactive states. Telomerase activity was detected in only 1 of 14 cases (7%) of lymphoid tissues involved by HD. Eight of the 13 negative cases were considered to be interpretable because of the lack (3 of 13 cases) or low level (5 of 13 cases) of telomerase inhibition. The five remaining cases could not be evaluated because of their telomerase inhibitor content. The findings imply either transient or very low levels of telomerase activity in HD or that HD for the greater part is a telomerase-independent neoplasm. Microdissection studies are needed to identify subsets of cells carrying telomerase activity in both reactive and neoplastic lymphoid tissues.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8978273

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Pilocytic astrocytomas have telomere-associated promyelocytic leukemia bodies without alternatively lengthened telomeres.

Authors:  Tania Slatter; Jennifer Gifford-Garner; Anna Wiles; Xin Tan; Yu-Jen Chen; Martin MacFarlane; Michael Sullivan; Janice Royds; Noelyn Hung
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

2.  HHV-8 is not associated with follicular dendritic cell tumours.

Authors:  S J Nayler; L Taylor; K Cooper
Journal:  Mol Pathol       Date:  1998-06

3.  The rate of telomere sequence loss in human leukocytes varies with age.

Authors:  R W Frenck; E H Blackburn; K M Shannon
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

4.  Three-dimensional Telomere Signatures of Hodgkin- and Reed-Sternberg Cells at Diagnosis Identify Patients with Poor Response to Conventional Chemotherapy.

Authors:  Hans Knecht; Narisorn Kongruttanachok; Bassem Sawan; Josée Brossard; Sylvain Prévost; Eric Turcotte; Zelda Lichtensztejn; Daniel Lichtensztejn; Sabine Mai
Journal:  Transl Oncol       Date:  2012-08-01       Impact factor: 4.243

5.  Down-regulation of telomerase activity in malignant lymphomas by radiation and chemotherapeutic agents.

Authors:  Z Lin; S Lim; M A Viani; M Sapp; M S Lim
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

6.  A non-isotopic method for the detection of telomerase activity in tumour tissues: TRAP-silver staining assay.

Authors:  J M Wen; L B Sun; M Zhang; M H Zheng
Journal:  Mol Pathol       Date:  1998-04

7.  Disruption of direct 3D telomere-TRF2 interaction through two molecularly disparate mechanisms is a hallmark of primary Hodgkin and Reed-Sternberg cells.

Authors:  Hans Knecht; Nathalie A Johnson; Tina Haliotis; Daniel Lichtensztejn; Sabine Mai
Journal:  Lab Invest       Date:  2017-04-24       Impact factor: 5.662

8.  Telomerase activity might persist in the human thymus throughout life.

Authors:  P Brousset; T al Saati; R C Zenou; G Delsol
Journal:  Mol Pathol       Date:  1998-06

9.  Selective killing of Burkitt's lymphoma cells by mBAFF-targeted delivery of PinX1.

Authors:  L Zhang; Y Jiang; Y Zheng; Y Zeng; Z Yang; G Huang; D Liu; M Gao; X Shen; G Wu; X Yan; F He
Journal:  Leukemia       Date:  2010-11-19       Impact factor: 11.528

10.  The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival.

Authors:  Janice A Royds; Shafagh Al Nadaf; Anna K Wiles; Yu-Jen Chen; Antonio Ahn; Alisha Shaw; Sara Bowie; Frederic Lam; Bruce C Baguley; Antony W Braithwaite; Martin R MacFarlane; Noelyn A Hung; Tania L Slatter
Journal:  PLoS One       Date:  2011-10-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.